About Accuronix
Accuronix is a company based in St. Louis (United States) founded in 2015.. Accuronix has raised $625 thousand across 2 funding rounds from investors including HHS, Missouri Technology and BioGenerator Ventures. Accuronix offers products and services including ACXT-3102 and Sigma-2 Receptor Platform. Accuronix operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter St. Louis, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Accuronix Therapeutics
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$625 K (USD)
in 2 rounds
-
Latest Funding Round
$2.25 M (USD), Grant
Sep 23, 2019
-
Investors
HHS
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Accuronix
Accuronix offers a comprehensive portfolio of products and services, including ACXT-3102 and Sigma-2 Receptor Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Small molecule for treating pancreatic cancer and rare tumors via apoptosis.
Platform delivering anti-cancer payloads to tumor cells for therapy development.
Unlock access to complete
Unlock access to complete
Funding Insights of Accuronix
Accuronix has successfully raised a total of $625K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $2.25 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $2.3M
-
First Round
First Round
(26 Jan 2016)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2019 | Amount | Grant - Accuronix | Valuation |
investors |
|
| Jan, 2016 | Amount | Seed - Accuronix | Valuation | BioGenerator |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Accuronix
Accuronix has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Missouri Technology and BioGenerator Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech companies focused VC firm operating across Missouri
|
Founded Year | Domain | Location | |
|
Venture capital and acceleration are provided to life science startups.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Accuronix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Accuronix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Accuronix Comparisons
Competitors of Accuronix
Accuronix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Accuronix
When was Accuronix founded?
Accuronix was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Accuronix located?
Accuronix is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
Is Accuronix a funded company?
Accuronix is a funded company, having raised a total of $625K across 2 funding rounds to date. The company's 1st funding round was a Seed of $625K, raised on Jan 26, 2016.
What does Accuronix do?
Accuronix was founded in 2015 in St. Louis, United States, within the biotechnology sector focused on oncology. Small molecule therapeutics are developed through a platform that conjugates these molecules to delivery probes targeting the sigma-2 receptor on cancer cells, enabling selective delivery of cytotoxic payloads. The lead candidate, des-methyl-erastin linked to a sigma-2 ligand, is undergoing preclinical testing for pancreatic tumors.
Who are the top competitors of Accuronix?
Accuronix's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Accuronix offer?
Accuronix offers ACXT-3102 and Sigma-2 Receptor Platform.
Who are Accuronix's investors?
Accuronix has 3 investors. Key investors include HHS, Missouri Technology, and BioGenerator Ventures.